Erratum: Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in guinea pigs (Journal of Virology (2011) 85:20 (10529-10541) Doi:10.1128/JVI.05050-11);Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in guinea pigs

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10529-10541

  Khattar, Sunil K ^a   Samal, Sweety ^a   DeVico, Anthony L ^b   Collins, Peter L ^c   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NEUTRALIZING ANTIBODY; OLIGOMER; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MUCOSAL IMMUNITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRION; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS VIRULENCE;

CAVIA; HUMAN IMMUNODEFICIENCY VIRUS 1; NEWCASTLE DISEASE VIRUS;

EID: 80055018755     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01868-19     Document Type: Erratum

References (73)

1. Alexander, D. J. 1989. Newcastle disease, 3rd ed. American Association for Avian Pathologists, University of Pennsylvania, Kennett Square, PA.
2. Alexander, D. J. 1997. Newcastle disease and other avian Paramyxoviridae infection, 10th ed. Iowa State University Press, Ames, IA.
3. Allan, J. S., et al. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-1094.
4. Baba, T. W., et al. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
5. Baba, T. W., et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
6. Binley, J. M., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
7. Bomsel, M., et al. 2011. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-280.
8. Bradac, J., and C. W. Dieffenbach. 2009. HIV vaccine development: lessons from the past, informing the future. IDrugs 12:435-439.
9. Bukreyev, A., and P. L. Collins. 2008. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 10:46-55.
10. Bukreyev, A., et al. 2005. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79:13275-13284.
11. Calain, P., and L. Roux. 1993. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67:4822-4830.
12. Carnero, E., et al. 2009. Optimization of human immunodeficiency virus gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 83:584-597.
13. Center, R. J., et al. 2002. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol. 76:7863-7867.
14. Center, R. J., et al. 2001. Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation. Proc. Natl. Acad. Sci. U. S. A. 98:14877-14882.
15. Cranage, M. P., et al. 2011. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29:1421-1430.
16. Cristillo, A. D., et al. 2011. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J. Gen. Virol. 92: 128-140.
17. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
18. de Leeuw, O., and B. Peeters. 1999. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 80(Pt. 1):131-136.
19. DiNapoli, J. M., et al. 2007. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. U. S. A. 104:9788-9793.
20. DiNapoli, J. M., et al. 2010. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84:1489-1503.
21. DiNapoli, J. M., et al. 2009. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27:1530-1539.
22. DiNapoli, J. M., et al. 2010. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29:17-25.
23. Dumais, N., A. Patrick, R. B. Moss, H. L. Davis, and K. L. Rosenthal. 2002. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 186:1098-1105.
24. Euler, Z., et al. 2011. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85:7236-7245.
25. Finerty, S., et al. 2001. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20: 49-58.
26. Forsell, M. N., et al. 2005. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by Semliki Forest virus. J. Virol. 79:10902-10914.
27. Gallo, R. C., and L. Montagnier. 2003. The discovery of HIV as the cause of AIDS. N. Engl. J. Med. 349:2283-2285.
28. Girard, M. P., S. K. Osmanov, and M. P. Kieny. 2006. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24:4062-4081.
29. Glenn, G. M., et al. 2007. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev. Vaccines 6:809-819.
30. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
31. Hinkula, J., M. Hagbom, B. Wahren, and U. Schroder. 2008. Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice. Vaccine 26:5101-5106.
32. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11:S45-S53.
33. Horner, A. A., et al. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167:1584-1591.
34. Hu, S. L., and L. Stamatatos. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5:507-513.
35. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2001. High-level expression of a foreign gene from the most 3′-proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 82:1729-1736.
36. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2003. Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J. Virol. 77:8676-8685.
37. Johnson, J. E., M. J. Schnell, L. Buonocore, and J. K. Rose. 1997. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol. 71:5060-5068.
38. Khattar, S. K., P. L. Collins, and S. K. Samal. 2010. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 28:3159-3170.
39. Kim, D., et al. 2011. Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies. J. Virol. 85:200-207.
40. Koopman, G., et al. 2007. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J. Med. Virol. 79:474-482.
41. Kozak, M. 1999. Initiation of translation in prokaryotes and eukaryotes. Gene 234:187-208.
42. Krishnamurthy, S., Z. Huang, and S. K. Samal. 2000. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278:168-182.
43. Krishnamurthy, S., and S. K. Samal. 1998. Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J. Gen. Virol. 79(Pt. 10):2419-2424.
44. Lehner, T., et al. 1999. The effect of route of immunization on mucosal immunity and protection. J. Infect. Dis. 179(Suppl. 3):S489-S492.
45. Lemiale, F., et al. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078-10087.
46. Li, M., et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccineelicited neutralizing antibodies. J. Virol. 79:10108-10125.
47. Li, Y., et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
48. Lorence, R. M., et al. 1994. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54:6017-6021.
49. Maamary, J., et al. 2011. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice. J. Virol. 85:2235-2246.
50. Mantis, N. J., P. A. Kozlowski, D. W. Mielcarz, W. Weissenhorn, and M. R. Neutra. 2001. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19:3990-4001.
51. Marinaro, M., et al. 2003. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 21:3972-3981.
52. Martinez-Sobrido, L., et al. 2006. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 80:1130-1139.
53. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
54. Murphey-Corb, M., et al. 1990. A formalin inactivated whole SIV vaccine and a glycoprotein-enriched subunit vaccine confers protection against experimental challenge with pathogenic live SIV in rhesus monkeys. Dev. Biol. Stand. 72:273-285.
55. Nakaya, T., et al. 2001. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75:11868-11873.
56. Nakaya, Y., et al. 2004. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J. Virol. 78:9366-9375.
57. Nayak, B., et al. 2010. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 84:2408-2420.
58. Nayak, B., et al. 2009. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 4:e6509.
59. Peeters, B. P., Y. K. Gruijthuijsen, O. S. de Leeuw, and A. L. Gielkens. 2000. Genome replication of Newcastle disease virus: involvement of the rule-ofsix. Arch. Virol. 145:1829-1845.
60. Phogat, S., and R. Wyatt. 2007. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13:213-227.
61. Pierson, T. C., and R. W. Doms. 2003. HIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281:1-27.
62. Pitisuttithum, P., et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
63. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
64. Robert-Guroff, M. 2007. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18:546-556.
65. Rout, S. N., and S. K. Samal. 2008. The large polymerase protein is associated with the virulence of Newcastle disease virus. J. Virol. 82:7828-7836.
66. Schoenly, K. A., and D. B. Weiner. 2008. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business." J. Virol. 82:3166-3180.
67. Staats, H. F., S. P. Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13:945-952.
68. Stevceva, L., and M. G. Ferrari. 2005. Mucosal adjuvants. Curr. Pharm. Des. 11:801-811.
69. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
70. Wegmann, F., et al. 2011. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. PLoS One 6:e15861.
71. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
72. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
73. Zhou, T., et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.